Gabapentin
Product Images NDC 50090-2590

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50090-2590). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Figure1)

This is a chart depicting mean pain scores during a study with a 4-week dose titration period followed by a 4-week fixed dose period. The chart compares the mean pain scores of a placebo group with a group taking 3600 mg/day of Gabapentin. The baseline pain score and pain scores at weeks 1 to 8 are shown on the chart.*

FDA Label Image

Figure2 (Figure2)

This is a chart related to a medication study where the dose of Gabapentin was titrated over a 3-week period and then a fixed dose was maintained for 4 weeks. There were 104 participants who either received a placebo or Gabapentin at either 1800mg/day or 2400mg/day. The chart displays the mean pain score over a duration of 7 weeks, including the baseline.*

FDA Label Image

Figure3 (Figure3)

The text describes a chart that shows the proportion of responders in controlled PHN studies at endpoint. The responders mentioned are the patients who have had more than 50% reduction in pain score. The chart consists of percentage values ranging from 0% to 100% in increments of 10. The chart describes two studies- 'Study 1' and 'Study 2'. Under study 1, 'GBP 3600' had 29% responders, 'PBO' had 12% responders. Under study 2, 'GBP 2400' had 34% responders, 'GBP 1800' had 14%, and 'PBO' had 3% responders. The text also mentions some statistical tests carried out which are not entirely discernible.*

FDA Label Image

Figure4 (Figure4)

FDA Label Image

Lbl500902590

FDA Label Image

Scale (Scale)

This text provides a formula for calculating estimated creatinine clearance (CLCr) for patients using their age and serum creatinine level, with a specific adjustment factor for female patients. Not much context is given for how this calculation is to be applied or why it might be useful.*

FDA Label Image

Structuralformula (Structuralformula)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.